Neohalo Biosciences
Hang Zhou Neohalo Biotechnology Co., Ltd. is a wholly-owned subsidiary of New Horizon Health(6606. HK), a listed company on the Hong Kong Stock Exchange. It was established in April 2022 and is located in the Zhejiang Pilot Free Trade Zone in China. Neohalo Biosciences is a supplier of reagents and instrument platforms focused on upstream nucleic acid research, mainly engaged in the development and promotion of nanomaterials and biochips, and serving public health and life sciences. The company is particularly committed to developing internationally leading reagents and equipment related to cfRNA research. Currently, it has launched a small RNA separation and purification kit based on the patented technology of silicon magnetic polymer (SMAGG) and a micro small RNA library construction kit based on the patented technology of linker self connected product removal. In the future, We will also launch a digital microfluidic technology platform based on the principle of dielectric wetting. In addition, the company has currently passed the ISO9001 quality management system, which ensures the stable and reliable quality of the developed products to the greatest extent possible, and helps to promote the rapid development of cfRNA detection applications.
-
R&D Capability
R&D Capability
Neohalo Biosciences focuses on developing industry-leading original detection technologies to serve public health and life sciences
-
Patent system
Patent system
Micro small RNA isolation and purification products based on patented nano magnetic bead technology and micro small RNA library construction products based on patented joint self linking product removal technology.
-
Platform construction
Platform construction
The company also has a 100000 level clean production workshop in Hangzhou, ensuring the stable and reliable quality of the developed products to the greatest extent, and assisting in the rapid development of small RNA detection applications.